BigHat Biosciences

BigHat Biosciences operates at the intersection of machine learning and synthetic biology, applying these disciplines to the engineering of therapeutic antibodies. The company's stated goal is to improve the design and development process for antibody drugs, aiming to produce candidates that are both safer and more effective than those discovered through conventional methods.

Central to the company's approach is its Milliner platform. This system integrates a wet laboratory with machine learning algorithms to manage the high-speed synthesis, purification, and characterization of recombinant antibodies. The platform is designed to process hundreds of antibodies within a single weekly workcell, a throughput intended to accelerate the discovery and optimization of drug candidates.

The company's work sits within the biotechnology and pharmaceutical sectors, focusing on the technical domains of machine learning, synthetic biology, and therapeutic antibody engineering. Its platform represents an effort to industrialize parts of the drug discovery pipeline that have traditionally been slower and more resource-intensive.